Yifan Xinfu Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Yifan Xinfu Pharmaceutical Co Ltd cash flow-to-debt ratio. Yifan Xinfu Pharmaceutical Co Ltd (002019) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥40.18 Million could theoretically repay 0% of its total liabilities (CN¥4.40 Billion) in one year. Check 002019 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Yifan Xinfu Pharmaceutical Co Ltd (2003–2025)
Cash flow-to-debt ratio of Yifan Xinfu Pharmaceutical Co Ltd from 2003 to 2025. Historical debt coverage capacity for Yifan Xinfu Pharmaceutical Co Ltd across 23 annual periods. Check 002019 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Yifan Xinfu Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2003–2025)
Yifan Xinfu Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Yifan Xinfu Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Yifan Xinfu Pharmaceutical Co Ltd (002019) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | CN¥458.37 Million | CN¥4.13 Billion | ▼ -33.2% |
| 2024 | 0.17x | CN¥640.73 Million | CN¥3.86 Billion | ▲ +54.5% |
| 2023 | 0.11x | CN¥348.58 Million | CN¥3.24 Billion | ▼ -22.7% |
| 2022 | 0.14x | CN¥472.07 Million | CN¥3.40 Billion | ▲ +56.4% |
| 2021 | 0.09x | CN¥301.23 Million | CN¥3.39 Billion | ▼ -76.0% |
| 2020 | 0.37x | CN¥1.11 Billion | CN¥2.99 Billion | ▲ +28.4% |
| 2019 | 0.29x | CN¥937.24 Million | CN¥3.24 Billion | ▼ -28.8% |
| 2018 | 0.41x | CN¥1.17 Billion | CN¥2.89 Billion | ▼ -28.9% |
| 2017 | 0.57x | CN¥1.13 Billion | CN¥1.99 Billion | ▲ +105.5% |
| 2016 | 0.28x | CN¥855.85 Million | CN¥3.08 Billion | ▲ +15.1% |
| 2015 | 0.24x | CN¥401.96 Million | CN¥1.67 Billion | ▲ +36.6% |
| 2014 | 0.18x | CN¥139.74 Million | CN¥791.21 Million | ▲ +48.3% |
| 2013 | 0.12x | CN¥34.32 Million | CN¥288.20 Million | ▲ +131.4% |
| 2012 | 0.05x | CN¥29.88 Million | CN¥580.73 Million | ▲ +167.9% |
| 2011 | -0.08x | CN¥-52.82 Million | CN¥696.73 Million | ▼ -11.6% |
| 2010 | -0.07x | CN¥-33.82 Million | CN¥497.79 Million | ▼ -126.4% |
| 2009 | 0.26x | CN¥58.61 Million | CN¥227.31 Million | ▼ -11.7% |
| 2008 | 0.29x | CN¥83.31 Million | CN¥285.39 Million | ▼ -60.6% |
| 2007 | 0.74x | CN¥248.71 Million | CN¥335.87 Million | ▲ +508.2% |
| 2006 | 0.12x | CN¥32.62 Million | CN¥267.92 Million | ▼ -1.1% |
| 2005 | 0.12x | CN¥24.12 Million | CN¥196.02 Million | ▼ -82.1% |
| 2004 | 0.69x | CN¥33.59 Million | CN¥48.72 Million | ▲ +470.5% |
| 2003 | 0.12x | CN¥12.65 Million | CN¥104.73 Million | — |